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Abstract
Background: Mesothelioma is an incurable, apoptosis-resistant cancer caused in most cases by previous exposure
to asbestos and is increasing in incidence. It represents a growing health burden but remains under-researched,
with limited treatment options. Early promising signals of activity relating to both PD-L1- and PD-1-targeted
treatment in mesothelioma implicate a dependency of mesothelioma on this immune checkpoint. There is a need
to evaluate checkpoint inhibitors in patients with relapsed mesothelioma where treatment options are limited.
Methods: The addition of 12 months of nivolumab (anti-PD1 antibody) to standard practice will be conducted in
the UK using a randomised, placebo-controlled phase III trial (the Cancer Research UK CONFIRM trial). A total of 336
patients with pleural or peritoneal mesothelioma who have received at least two prior lines of therapy will be
recruited from UK secondary care sites. Patients will be randomised 2:1 (nivolumab:placebo), stratified according to
epithelioid/non-epithelioid, to receive either 240 mg nivolumab monotherapy or saline placebo as a 30-min
intravenous infusion. Treatment will be for up to 12 months. We will determine whether the use of nivolumab
increases overall survival (the primary efficacy endpoint). Secondary endpoints will include progression-free
survival, objective response rate, toxicity, quality of life and cost-effectiveness. Analysis will be performed
according to the intention-to-treat principle using a Cox regression analysis for the primary endpoint (and
for other time-to-event endpoints).
Discussion: The outcome of this trial will provide evidence of the potential benefit of the use of nivolumab
in the treatment of relapsed mesothelioma. If found to be clinically effective, safe and cost-effective it is likely
to become the new standard of care in the UK.
Trial registration: EudraCT Number: 2016–003111-35 (entered on 21 July 2016); ClinicalTrials.gov, ID: NCT03063450.
Registered on 24 February 2017.
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Background
Mesothelioma is an incurable, apoptosis-resistant cancer
caused in most cases by previous exposure to asbestos
and is increasing in incidence in the UK and beyond [1,
2]. The majority of patients with mesothelioma present
with advanced disease and prognosis is poor, especially
with sarcomatoid mesothelioma. Mesothelioma therefore
represents a growing health burden, but it remains under-
researched and treatment options are limited. Chemother-
apy is currently the standard of care in the first-line setting
in which two positive, randomised phase III trials have
been reported, showing improved survival with the
addition of pemetrexed or raltitrexed to cisplatin, respect-
ively [3, 4]. The recent French MAPS trial has shown that
the addition of bevacizumab to pemetrexed-cisplatin and
bevacizumab maintenance, improves survival from 16.
1 months within the control arm to 18.8 months with the
addition of bevacizumab [5].
Unfortunately, even following successful first-line ther-
apy, all patients with mesothelioma will subsequently re-
lapse. There is currently no standard second-line therapy;
however, it is common practice to re-challenge with the
first-line regimen, usually pemetrexed-cisplatin, if there
has been a reasonable progression-free interval. In
addition to this, vinorelbine is used in some centres, as
phase II trials have shown this drug to have promising ac-
tivity in the second-line treatment of mesothelioma. Cur-
rently the Vinorelbine In Mesothelioma study (VIM study:
NCT02139904) trial is ongoing to evaluate its efficacy in
this setting. Due to the availability of second-line options,
either within the VIM trial or off study, the CONFIRM
trial aims to evaluate immunotherapy in the third-line set-
ting, a clinical situation in which current standard of care
is active symptom control only. Thus, best supportive care
has been chosen as the comparator arm in this study.
The landscape of cancer therapy has been recently
transformed by the emergence of immunotherapy involv-
ing the targeting of immune checkpoints [6–8]. Pro-
grammed cell death 1 (PD-1) is a 55-kDa transmembrane
inhibitory immunoreceptor expressed by activated T cells
that negatively regulates immune responses required for
peripheral self-tolerance. PD-1 interacts with its ligand
PD-L1, a member of the B7 gene family, which is
expressed on mesothelioma cells [9, 10]. The expression
of PD-L1 (> 5% positively stained cells) has been reported
in 40% of mesothelioma overall, with a higher rate in sar-
comatoid mesotheliomas and is a poor prognostic factor.
The PD-1-PD-L1 axis mediates an inhibitory signal to T
cells leading to induction of apoptosis via PD-1 activation.
Accordingly, PD-1 or PD-L1 blockade de-represses T-cell
activation, unleashing a clinical immune response with
tumour regression [11].
Targeting the PD-1 in mesothelioma has demonstrated
promising efficacy. Of 25 patients receiving pembrolizumab
in a single-arm phase I/II study (Keynote 28 (KN028)),
the objective response rate was 20% in patients with
PD-L1-positive malignant pleural mesothelioma (≥ 1%
PD-L1-positive tumour cells by immunohistochemis-
try). Additionally, 52% of patients had stable disease,
resulting in a disease control rate of 72% [12].
PD-L1 blockade has also demonstrated promising effi-
cacy in patients with mesothelioma [13]. In a phase IB
study (NCT01772004), 53 patients were treated with avelu-
mab (MSB0010718C, Merck Serono), with histologically or
cytologically confirmed unresectable mesothelioma (pleural
or peritoneal) that progressed after a prior platinum-
pemetrexed-containing regimen or a platinum-based regi-
men followed by pemetrexed. Avelumab was administered
at a dose of 10 mg/kg as a 1-h infusion every two weeks
(q2w) until confirmed progression, unacceptable toxicity,
or any criteria for withdrawal occurred. Patients had re-
ceived a median of 1.5 prior treatments (range, 0–7.4).
Histology was epithelial (81.1%), mixed (11.3%) or sarcoma-
toid (3.8%). Objective responses were observed in 5 (9.4%)
patients; all were partial responses (PR) and durable. Stable
disease (SD) was observed in 9 additional patients (45%).
The overall disease control rate (PR plus SD) was 56.6% (30
patients). Median progression-free survival (PFS) by Re-
sponse Evaluation Criteria in Solid Tumours (RECIST) was
17.1 weeks (95% CI 6.1–30.1), and the PFS rate at 24 weeks
was 38.4% (95% CI 23.3, 53.4).
Nivolumab is a human IgG4 anti-PD1 monoclonal
antibody which blocks the PD-1 receptor on activated T
cells, which has been approved by the Food and Drug
Administration for the treatment of patients with unre-
sectable or metastatic melanoma unresponsive to other
drugs, and relapsed non-small-cell lung cancer, recurrent
renal cancer and lymphoma. In a phase IIA clinical trial
of nivolumab (3 mg/kg every two weeks (q2w) con-
ducted at NKI, Amsterdam, the disease control rate at
12 weeks was 50% (n = 34) [14].
In summary, there is a need to find effective, safe, cost-
effective interventions for individuals with mesothelioma.
Using a two-arm, parallel-group randomised phase III trial
(CONFIRM trial), we will compare nivolumab with
placebo in patients with relapsed mesothelioma.
Methods/design
This study protocol was written in accordance with
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT). A SPIRIT checklist is provided
in Additional file 1.
Objectives
The main aim of the CONFIRM trial is to evaluate the
efficacy, safety and cost-effectiveness of treatment with
nivolumab in patients with relapsed mesothelioma.
Fennell et al. Trials  (2018) 19:233 Page 2 of 10
Study design
CONFIRM is a double-blind, placebo-controlled rando-
mised phase III trial comparing nivolumab monotherapy
versus placebo until disease progression, for a maximum
of 12 months. Patients will be randomised by pharmacy
staff at site using an Interactive Web Response System
(IWRS) which will allocate participants in a 2:1 ratio to
either the nivolumab or the control arm using the
method of permuted blocks (NB. All investigators are
blinded to the block size and stratification factors used
until the end of the trial); see Fig. 1. Patients, clinicians
and trial management staff will be blinded to treatment
allocation. Treatment allocation will be unblinded only if
there is a clinical reason that will affect decisions about
how to proceed with patient care.
CONFIRM is being run in approximately 25 UK cen-
tres with the aim of recruiting a total of 336 patients.
CONFIRM has received ethical approval by the West
Midlands – Edgbaston Research Ethics Committee (16/
WM/0472) and has approval from the UK Medicines and
Health Care Product Regulatory Agency (MHRA) to be
conducted in the UK. Southampton Clinical Trials Unit
(SCTU), a Cancer Research UK core-funded and UK Clin-
ical Research Collaboration-registered CTU, is coordinating
the trial. The University of Southampton is the sponsor for
the trial https://www.southampton.ac.uk/research/ris.page.
Fig. 1 Trial schema
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An independent Trial Steering Committee and Independ-
ent Data Monitoring Committee comprising two clinicians
and a statistician experienced in this research area has been
set up to monitor trial progress and safety. The CONFIRM
Trial Management Group includes representatives from
medical and clinical oncology, radiology, health economics
and CTU staff involved in the day-to-day running of the
trial. Charters for these groups are available via confirm-
trial@soton.ac.uk.
The SCTU has undertaken a risk assessment for the
CONFIRM trial which includes the requirements for
monitoring (both central and site). The SCTU under-
takes a number of internal audits of its own systems and
processes annually and has routine audits from both its
sponsor and the independent MHRA every 2–3 years.
Primary outcome measure
The primary efficacy endpoint will be overall survival
(OS – time to event). OS will be calculated as the time
from randomisation to death from any cause. Those still
alive will be censored at the time last known to be alive.
NB. In addition to receiving participant data direct from
treating hospitals we have also registered participants
with England’s NHS Digital, or an equivalent in Wales,
Scotland and Northern Ireland, to obtain primary out-
come survival data.
Secondary outcome measure
The secondary outcome measures are as follows:
 OS according to PD-L1 status
 Progression-free survival (PFS – time to event). PFS
will be calculated from the date of randomisation to
the date of disease progression (using modified
RECIST or RECIST 1.1) or any death (whichever
event comes first). Those still alive and progression
free will be censored at the last time seen. Regular
computerised tomography (CT) scans will not be
mandated. Follow-up imaging will be as per local
hospital policy and as clinically indicated
 Objective response rate (ORR) – assessed using
modified RECIST or RECIST 1.1 during treatment
and post treatment
 Quality of life (QoL) – assessed using EQ-5D-5L
at baseline, after treatment cycles 3 and 6 and
then at 28 days, 6 months and 1 year post treatment
discontinuation. The EQ-5D-5 L assesses five
dimensions: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression
 Toxicity – assessed using Common Terminology
Criteria for Adverse Events (CTCAE) v4.03 at
baseline, after each treatment cycle and at each
follow-up visit
 Treatment compliance – assessed using treatment
compliance Electronic Case Report Forms (eCRFs)
during the treatment period
 Cost-effectiveness – assessed using plus EQ-5D-5 L
and data on health resource usage during treatment
and post discontinuation to calculate a cost per
quality-adjusted life year (QALY)
Sample size
The study aims to demonstrate that nivolumab will in-
crease median overall survival (OS) of patients with re-
lapsed mesothelioma from 6 months (estimated median
OS [15]) to 8.5 months, equivalent to increasing the 6-
month OS rate from 50% to 61.5%. To detect a hazard
ratio (HR) of 0.70 with 80% power at a 4% two-sided sig-
nificance level requires a total of 291 events (deaths).
Recruiting 336 patients – randomised 2:1 (221 receiving
nivolumab: 112 receiving placebo) – over a 4-year period
and 6 months’ follow-up, should be sufficient to achieve
this number of events.
It is anticipated that 40% of patients will be PD-L1
checkpoint positive [16]. This will allow us to have 80%
power to detect a HR of 0.5 (p = 0.01) in OS, equivalent
to increasing the 6 months OS rate from 50% to 70.7%.
The number of patients required for this subgroup is
132 (88 nivolumab: 44 placebo) to achieve a total of 105
events (deaths).
Another important subgroup analysis to assess at the
end of the trial is the OS of patients with a high PD-L1 ex-
pression of ≥ 50% (25% of patients are anticipated to have
a high PD-L1 expression of ≥ 50%). The sample size will
allow us to have 80% power in this subgroup to detect a
HR of 0.4 (p = 0.01) in OS, equivalent to increasing the
6 months’ OS rate from 50% to 75.8% (i.e. number of pa-
tients in this subgroup is 78 (52 receiving nivolumab; 26
receiving placebo) with 59 events (deaths).
The trial is registered on the UK NIHR trial portfolio
meaning that there are research nurses based at UK can-
cer hospitals who help in screening potential patients to
identify those eligible for the trial.
Study participants
Inclusion criteria
Participants should fulfil all the following criteria:
 Histological confirmation of mesothelioma (any
subtype, pleural or peritoneal)
 Male or female ≥ 18 years old
 Patients must have received at least two prior lines
of treatment (including patients who have had re-
challenge with platinum/pemetrexed). Prior
maintenance therapy is permitted but will not
count as a line of treatment
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 Prior lines of antineoplastic therapy, including
chemotherapy, surgical resection of lesions,
radiation therapy, must be completed at least
14 days prior to receiving study treatment
 Eastern Cooperative Oncology Group Performance
Status (ECOG PS) 0–1
 Radiologically assessable disease by modified RECIST
(pleural mesothelioma) or RECIST 1.1 (non-pleural
mesothelioma or where measurements for mRECIST
cannot be obtained). Radiological tumour assessment
(CT scan) must be performed within 28 days of first
dose of study treatment
 Evidence of disease progression by CT scan
 Prior palliative radiotherapy must have been completed
at least 14 days prior to study drug administration
 Patients must be willing and able to comply with
scheduled visits, treatment schedule, laboratory tests
and other requirements of the study
 Screening laboratory values must meet the following
criteria within 48 h prior to commencement of
treatment: white blood cells ≥ 2 × 109/L; neutrophils
≥ 1.5 × 109/L; platelets ≥ 100 × 109/L; haemoglobin ≥
90 g/L; serum creatinine ≤ 1.5 × ULN or creatinine
clearance (CrCl) > 50 mL/min (using the Cockcroft/
Gault formula); female CrCl = [(140 − age in years)
× weight in kg × 0.85) ÷ (72 × serum creatinine in
μmol/L)]; male CrCl = [(140 − age in years) × weight
in kg × 1.00) ÷ (72 × serum creatinine in μmol/L)];
aspartate aminotransferase (AST) ≤ 3 × ULN; alanine
aminotransferase (ALT) ≤ 3 × ULN; total bilirubin ≤
1.5 × ULN (except patients with Gilbert syndrome,
who must have total bilirubin < 51.3 μmol/L)
 Expected survival of at least 12 weeks
 Appropriate contraception, negative pregnancy tests
if of child-bearing potential and not breastfeeding
 Written informed consent, including use of tissue
and blood samples for research
Exclusion criteria
Individuals meeting any of the following criteria will be
excluded:
 Patients with untreated, symptomatic central nervous
system (CNS) metastases, carcinomatous meningitis
or active, known or suspected autoimmune disease.
Participants are eligible if central nervous system
(CNS) metastases are adequately treated and
participants are neurologically returned to baseline
(except for residual signs or symptoms related to the
CNS treatment) for at least 2 weeks prior to
treatment assignment. Participants must be either
off corticosteroids, or on a stable or decreasing
dose of less than or equal to 10 mg daily (or
equivalent) for at least 2 weeks prior to treatment
 Patients with a condition requiring systemic treatment
with either corticosteroids (> 10 mg daily prednisone
equivalent) or other immunosuppressive medications
within 14 days of the first dose of study drug
administration
 Patients with active malignancy requiring concurrent
intervention or previous malignancies (except
non-melanoma skin cancers, and the following in-
situ cancers: bladder, gastric, colon, endometrial,
cervical/dysplasia, melanoma or breast) unless a
complete remission was achieved at least 2 years
prior to study entry and no additional therapy is
required during the study period
 Any serious or uncontrolled medical disorder or active
infection that, in the opinion of the investigator, may
increase the risk associated with study participation,
study drug administration, or would impair the ability
of the patient to receive protocol therapy
 All toxicities attributed to prior anti-cancer therapy,
other than alopecia and fatigue, not resolved to
grade 1 (NCI CTCAE version 4.03) or baseline
before administration of study drug
 Patients who have not recovered from the effects of
major surgery or significant traumatic injury at least
14 days before the first dose of study treatment
 Known alcohol or drug abuse
 Patients who have received prior therapy with anti-
PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-
CTLA-4 antibody (including ipilimumab or any
other antibody or drug specifically targeting T-cell
co-stimulation or checkpoint pathways) or who have
previously taken part in a randomised Bristol
Myers Squibb (BMS) clinical trial for nivolumab
or ipilimumab including study CA209–743
(CheckMate 172)
 Testing positive for human immunodeficiency virus
or known acquired immunodeficiency syndrome, or
hepatitis B virus or hepatitis C virus indicating acute
or chronic infection
 History of severe hypersensitivity reactions to other
monoclonal antibodies
Withdrawal criteria
The participant/legal representative is free to withdraw
consent from the study at any time without providing a
reason. A participant could also withdraw from treat-
ment but allow continuation of collection of data.
Study procedure
Recruitment and consent
Patients are approached within a hospital setting and
screened for eligibility by research staff to ensure that all
inclusion and exclusion criteria are met. Informed
consent to enter the trial is obtained from a patient by a
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clinician only after a full explanation has been given, an
information leaflet offered and time allowed for consid-
eration. Patients consent to provision of tumour and
blood samples for use in laboratory studies including
genetic analysis and for their data to be shared anonym-
ously to support other research in the future (see
Additional file 2). A list of study sites is available on
request from confirmtrial@soton.ac.uk.
Baseline visit
Following informed consent, a CT scan with modified
RECIST (pleural mesothelioma) or RECIST 1.1 (non-
pleural mesothelioma) will be undertaken within 28 days
of treatment. Participants will undergo physical examin-
ation including vital signs, oxygen saturation, measure-
ment of height, weight, oxygen saturation and ECOG
PS. Concomitant medications and medical history, in-
cluding smoking history, exposure to asbestos and
chronic pulmonary and cardiovascular diseases will be
recorded. Safety assessments comprising full blood
count, serum chemistry tests, liver and thyroid function
tests will all be performed before randomisation. In
addition, women of child-bearing potential will under-
take a pregnancy test. Participants will be randomised
within 48 h prior to commencement of treatment.
Following randomisation participants will complete the
European Quality of Life-5 Dimensions-5 Levels (EQ-
5D-5 L) questionnaire and a formalin-fixed paraffin-
embedded tumour-tissue block will be obtained, either
archival or fresh if no archival sample is available.
Follow-up visits
Participants will attend hospital appointments for treat-
ment every 14 days during treatment, 28 days post pro-
gression/treatment discontinuation, 6 months and
12 months (see Fig. 2). The follow-ups during the treat-
ment period (i.e. until progression) will collect data
required for the primary and secondary endpoints
including disease assessments (NB. A CT scan will be
carried out of chest and abdomen for all participants
and for pelvis for patients with peritoneal mesothelioma)
, standard physical examinations, pregnancy tests (if
appropriate), treatment compliance, ECOG PS, labora-
tory tests (e.g. urea, electrolytes, liver function, oxygen
saturation, serum biochemistry, full blood count, lactate
dehydrogenase (LDH) and C-reactive protein (CRP)) and
adverse events. The participant will then enter a post-
treatment/progression follow-up to collect data on
adverse events, quality of life (QoL), health resource use
and survival status. Serious adverse event (SAE)
Fig. 2 Schedule of procedures
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reporting is in real time to the SCTU safety desk
throughout the study. SAEs are assessed to determine if
related to drug treatment and whether unexpected or
not, and subsequently reported to both BMS and the UK
regulatory bodies.
Data collection
Research staff at hospitals will complete trial eCRFs via a
remote data collection tool (Medidata Rave). Data will
be checked for missing or unusual values and checked
for consistency within participants over time by SCTU
trial staff. Any suspect data will be raised as data queries.
Site staff will respond to the queries providing an
explanation/resolution of the discrepancies. Full details
on data management procedures are available in the
Data Management Plan, available on request.
Intervention
Nivolumab
Participants will receive nivolumab at a dose of 240 mg
as a 30-min intravenous (IV) infusion, on day 1 ± 2 of
every 14-day treatment cycle, until progression, un-
acceptable toxicity, withdrawal of consent, or the max-
imum treatment duration of 12 months is reached,
whichever occurs first. There will be no dose escalations
or reductions allowed. Patients may be dosed no less
than 12 days from the previous dose.
The infusion must be administered through a sterile,
non-pyrogenic, low-protein-binding, in-line filtre with a
pore size of 0.2–1.2 μm. It should not be administered
as an IV push or bolus injection. The total dose can be
infused directly as a 10 mg/mL solution or can be di-
luted to as low as 1 mg/mL with sodium chloride 9 mg/
mL (0.9%) solution for injection or glucose 50 mg/mL
(5%) solution for injection. After administration the line
should be flushed with sodium chloride 9 mg/ml (0.9%)
solution for injection or 50 mg/ml (5%) glucose solution
for injection. Participants should be carefully monitored
for infusion reactions during administration.
Control
Patients who are randomised to receive placebo will re-
ceive sterile 0.9% sodium chloride as a 30-min IV infu-
sion (as per the nivolumab treatment process).
Prohibited and restricted therapies during the trial
(unless utilised to treat a drug-related adverse event) in-
clude immunosuppressive agents, any concurrent anti-
neoplastic therapy and live vaccinations. Caution must
be used with ototoxic or nephrotoxic concomitant drugs
and discontinuation of the use of herbal medications
prior to study enrolment is encouraged. Inhaled or top-
ically administered steroids, and adrenal replacement
steroid doses > 10 mg daily prednisone equivalent, are
permitted in the absence of active autoimmune disease.
The use of topically, ocularly, intra-articularly, intrana-
sally and inhalationally administered corticosteroids
(with minimal systemic absorption) or adrenal replace-
ment steroid doses > 10 mg daily prednisone are permit-
ted. A less than 3-week course of corticosteroids for
prophylaxis (e.g. contrast-dye allergy) or for treatment of
non-autoimmune conditions (e.g. delayed-type hyper-
sensitivity reaction caused by a contact allergen) is per-
mitted as is regular concomitant use of bisphosphonates
and RANK-L inhibitors for prevention or reduction of
skeletal-related events in patients with bone metastases
if initiated prior to the first dose of study therapy.
Statistical analysis
Analyses will be intention-to-treat (ITT), consisting of
all patients who have consented and have been rando-
mised to a treatment arm. Safety analyses will include
patients who have received at least one dose of study
treatment.
Time-to-event data (OS, PFS) will be analysed and pre-
sented using Kaplan-Meier curves for the ITT population.
A Cox proportional hazards model will be used to calcu-
late the HR, 95% confidence intervals and p value, both
unadjusted and adjusted (for the randomisation stratifica-
tion factor epithelioid/non-epithelioid). The adjusted Cox
regression model for OS will form the primary endpoint
analysis model (and for the pre-specified PD-L1
checkpoint-positive subgroups). Subgroup analyses will be
undertaken in patients with negative (PD-L1 < 1%),
medium (1–49%) and high (≥ 50%) PD-L1 expression,
using a Cox regression model for OS and PFS adjusted for
the randomisation stratification factor.
For the secondary endpoints of toxicity, ORR, QoL
and treatment compliance we will compare proportions
for categorical data and means/medians for continuous
data using the Pearson’s χ2 test and T test/Mann-
Whitney U test, respectively.
There will be no missing data imputation as the pri-
mary endpoint (and some of the secondary endpoints)
is/are time-to-event data which censors at the time last
seen without an event and so is included in the analysis.
Interim analysis
The efficacy data for the PD-L1 expression-positive sub-
group will be reviewed at two time points: after approxi-
mately 40% (n ≈ 54) and 70% (n ≈ 94) of patients in the
PD-L1 expression-positive subgroup have been recruited
and followed up for 6 months. The p value of < 0.001 is
the Peto-Haybittle rule recommended in Pocock [17],
allowing proof beyond reasonable doubt. We are plan-
ning on using this p value for both stopping guidelines
(a symmetrical stopping boundary) as should evidence
of harm or benefit arise, it needs to be sufficiently con-
vincing to ensure that others will believe it and change
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their practice accordingly. In addition, a p value of < 0.
001 is sufficiently small to preserve the p value of 0.04
for the final analysis with two interim analyses.
The IDMC will monitor the trial for futility. The
method to use for these analyses will be planned and
agreed with the IDMC and is likely to be based on the
approach described by Freidlin [18]. It is anticipated that
the first futility analysis (for harm) will take place after
25% of events have been observed, followed by a futility
analysis after 46% of events of observed (t0 from Frei-
dlin’s paper using 4% two-sided significance and 80%
power), and a futility analysis after 73% of events of
observed (t1 from Freidlin’s paper). The patients to be
included in these futility analyses will be agreed with the
IDMC. It is anticipated that all patients who have been
randomised will be included in these analyses.
All analyses will be carried out using STATA 15.
Health economic analysis
The economic analysis will include: (1) a ‘within-trial’
cost-effectiveness analysis, to compare the costs and
health outcomes (QALYs) accrued over the follow-up
period for patients in the intervention and control arms
and (2) development of a cost-effectiveness model to ex-
trapolate cost and QALY estimates over a lifetime hori-
zon. The analyses will follow the recommended methods
and ‘reference case’ recommended by NICE, including:
an NHS and Personal Social Services perspective for
costing; estimation of QALYs using EQ-5D data and UK
value sets, and discounting of costs and QALYs at 3.5%
per year. The ‘within-trial’ analysis will be pre-specified,
and will take into consideration the need for multiple
imputation for missing data, adjustment for baseline co-
variates, inclusion of an interaction term for pre-
specified subgroups (e.g. high expressers of PD-L1), and
the possibility of clustering by centre. Results will be
presented as a ratio – the incremental cost per QALY
gained with nivolumab compared with no treatment.
Non-parametric bootstrapping will be used to obtain
estimates of joint uncertainty over mean costs and
QALYs, which will be represented by a scatterplot on
the cost-effectiveness plane, and as a cost-effectiveness
acceptability curve (CEAC), showing the probability that
nivolumab is cost-effective as a function of willingness
to pay per QALY (the cost-effectiveness ‘threshold’). The
cost-effective modelling will be conducted according to
International Society for Pharmacoeconomics and Out-
comes Research guidelines and probably take the form
of a ‘Markov-type’ health state transition model, al-
though we will consider whether an individual-level
simulation model will add value. Probabilistic sensitivity
analysis will be used to estimate how uncertainty over
input parameters results in uncertainty over the model
results. Modelling results will also be presented as an
incremental cost-effectiveness ratio, and with a cost-
effectiveness scatterplot and CEAC curve.
Translational analysis
Samples will be sent to the central laboratory where they
will be stored and analysed. The goals of the translational
research will be to determine the correlation between over-
all survival and: (1) PD-L1 expression; (2) mutational bur-
den (estimated by genome-wide analysis of copy number
alterations) and (3) immunotranscriptomic profile. Further
studies involving analysis of circulating inflammatory bio-
markers, and tumour microenvironment interrogation
using multiplex immunohistochemistry and transcriptome
analysis, are also planned.
Adverse event reporting
Data on adverse events will be collected at treatment
and follow-up visits. The trial also has a UK regulatory
compliant real-time serious adverse events reporting
process to identify serious adverse reactions and sus-
pected unexpected serious adverse reactions that could
suspend/stop the trial if warranted.
End of the trial
The end of trial is defined as when the last patient has
had their last data collected.
Discussion
Effective therapy for relapsed mesothelioma is an unmet
need. Despite a significant number of clinical studies in
the second-line setting, no randomised study to date has
been positive.
The James Lind Alliance Priority Setting Partnership,
funded by the National Institute for Health Research,
has identified immunotherapy as the number-one UK
research priority. To date there have been no placebo-
controlled randomised trials for mesothelioma using
PD-L1 or PD-1 checkpoint inhibition. Early promising
signals of activity relating to both PD-L1- and PD-1-
targeted treatment in mesothelioma implicate a depend-
ency of mesothelioma on this immune checkpoint, and
support the development of a randomised phase III trial
to evaluate the efficacy of nivolumab.
PD-1 checkpoint inhibition has revolutionised the treat-
ment of melanoma and is expected to become standard of
care in NSCLC. It is being assessed rigorously in numerous
other cancer sites, making its evaluation in mesothelioma
timely in this trial. CONFIRM is the first-ever placebo-
controlled, randomised phase III trial of a PD-1 immune-
checkpoint inhibitor in mesothelioma (relapsed and non-
relapsed). The outcome of this trial will provide evidence
of the potential benefit of the use of nivolumab in the treat-
ment of relapsed mesothelioma. If found to be clinically
effective, safe and cost-effective it is likely to become the
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new standard of care in the UK. A potential limitation of
the trial in the future could be the use of overall survival as
the primary endpoint if there is any treatment crossover, as
either patients on the placebo have access to immunother-
apy outside of the trial or new evidence emerges that
patients can be effectively re-challenged with new
immunotherapy treatment combination on progression.
We are currently seeking funding to add a translational
component onto the trial to collect and analyse samples
taken at progression to decipher mechanisms that lead to
acquired resistance, and that might provide a rationale for
new interventions following checkpoint-inhibitor failure.
Post-progression immunotherapy (or indeed other active
agents such as re-challenge pemetrexed-platinum), either
by design or patient access outside of the trial, could bias
the overall survival analysis. We are mitigating against this
by collecting, and reporting to the Independent Data Mon-
itoring Committee, any instances of additional treatment
received by patients in each arm, and collecting detailed
PFS outcome data, which could be used as an appropriate
unbiased endpoint to compare the existing arms should a
case be put to the funder to include an additional post-
progression randomisation during the life of the trial.
Results will be disseminated to patients and clinical
teams through peer-reviewed journal publications and
by engaging with specialist organisations, such as Meso-
thelioma UK.
Trial status
This clinical trial was registered in February 2017
(ClinicalTrials.gov, ID: NCT03063450 and ISRCTN
79814141). Recruitment opened on 28 March 2017
and is expected to be completed in March 2021). The
current protocol is version 3, dated 8 February 2018.
REC/MHRA-approved protocol amendments will be
communicated to sites via email and updated trial docu-
mentation provided centrally via the trial website. Trial
registries will be amended where relevant with explana-
tions for these changes. Results will be published at the
end of the trial in a peer-reviewed journal (authored by
the members of the TMG), presented at international con-
ferences; end of trial summaries will appear on regulatory
authority databases and results fed back to recruiting sites
so that any participants are able to access the results via
their treating clinician.
Additional files
Additional file 1: SPIRIT Checklist. (DOC 121 kb)
Additional file 2: Informed Consent Form. (PDF 133 kb)
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